IRVINE, Calif. and OXFORD, Miss., June 9, 2011
/PRNewswire/ — ChromaDex Corp. (OTCBB: CDXC) and the
University of Mississippi today announced the university has
granted the natural products company the exclusive worldwide patent
rights to a potential new therapeutic use for pterostilbene
(tero-STILL-bean) as an anxiolytic or anti-anxiety agent.
ChromaDex’ pTeroPure® is an ultra-pure formulation of
pterostilbene, a compound found in blueberries and demonstrated to
have multiple health benefits.
ChromaDex continues its strategy of expanding its intellectual
property supporting pterostilbene as the company builds its
pTeroPure product portfolio and seeks partnerships to enter new
markets. ChromaDex previously licensed two patents from the
University of Mississippi that focus on the ability of
pterostilbene to reduce blood lipoprotein levels and
pterostilbene’s effect on oxidative stress and cognition. ChromaDex
also holds rights to patents related to manufacturing claims.
“Adding the anxiolytic indication to our existing patent
portfolio around pTeroPure allows us to capitalize on new product
opportunities that we can pursue independently or with partners
looking to differentiate their own products,” said ChromaDex
President William Spengler. “ChromaDex will continue to seek
partners such as the University of Mississippi so as to capture
advancements in natural product research that will allow us to
provide the marketplace with innovative proprietary
ingredients.”
Research conducted by the University of Mississippi School of
Pharmacy shows pterostilbene may have anxiolytic activities. The
researchers determined pterostilbene activates the ERK signaling
pathway in the hippocampus, an area of the brain speculated to play
a role in anxiety. The effect of pterostilbene was investigated in
a classic animal model of anxiety and found to be comparable in
activity to the anti-anxiety drug diazepam used as the control drug
in the mod
‘/>”/>
